The WHO (World Health Organization) classifies allergies as the fourth most important chronic disease in the world. Allergic rhinitis (AR) is the most common form of non-infectious rhinitis, affecting between 10% and 30% of all adults and as many as 40% of children. Epidemiologic studies show that the prevalence of AR is expected to be still important in the next decades. The World Allergy Organization (WAO) has estimated that 400 million people in the world suffer from AR (1).


The prevalence of asthma, allergic rhinitis and atopic dermatitis has been increasing over the last four decades, both in the industrialized and developing countries. It seems to be related to changes in the social structure, in-creasing industrialization, pollution and dietary changes (2).

Allergic rhinitis social burden is considerable with negative impacts on sleep, mood, social functioning, work/school performance and health-related quality of life.

Seasonal Allergic rhinitis (SAR; commonly called hay fever) is characterized by runny nose, congestion, sneezing and sinus pressure. SAR is caused by an allergic response to outdoor allergens, such as pollens. Allergic conjunctivitis is an increasingly prevalent allergic disease, with the same clinical gravity as allergic asthma and allergic rhinitis. The umbrella term “allergic conjunctivitis” includes distinct clinical entities, from mild but disturbing forms to severe keratoconjunctivitis. Untreated allergic rhinitis can lead to more serious diseases in the upper and lower airways. It is often associated with asthma, nasal polyps, sinusitis and otitis media. First-line treatment for AR consists in the identification and avoidance of provoking allergens, together with the use of decongestants and second-generation antihistamines, while second-line therapy includes corticosteroids (intranasal/oral/injected), LTAs (leukotriene antagonists) and anticholinergics. All of the above treatments cause side effects.


Copyright © Innovus Pharmaceuticals, Inc.
8845 Rehco Road San Diego, CA 92121 USA
Telephone: 1.800.996-5122.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Please talk to your doctor before taking AllerVarx®. AllerVarx® is not a drug- it is a dietary supplement. In a published clinical trial, AllerVarx® has been used safely with minor side effects. Do not use if you are allergic to any ingredients of AllerVarx®. Pregnant women and women who are nursing should not take supplements including AllerVarx® without first talking to their doctor. Do not exceed the recommended dose. Take with food.